Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021242 · ClinicalTrials.gov registry record · Phase 2
Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00021242 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 12 participants.
The verdict
NCT00021242, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating children who have relapsed or refractory acute lymphoblastic or acute myeloid leukemia.
Interventions
- DRUG docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2002-08 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021242
The ClinicalTrials.gov registry entry for NCT00021242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which docetaxel is the first listed.
NCT00021242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021242 about?
NCT00021242 is a clinical study titled "Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating children who have relapsed or refractory acute lymphoblastic or acute myeloid ...
What is the current status of trial NCT00021242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2002-08. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00021242?
The interventions under investigation include: docetaxel (DRUG).
Who is sponsoring clinical trial NCT00021242?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.